


# 9M 2023 Results

Swiss Re investor and analyst presentation Zurich, 3 November 2023




## Strong third quarter result supported by all businesses




		Q3 2023 key figures	9M 2023 key figures	FY 2023 targets
P&C Reinsurance	Combined ratio	93.7%	94.3%	<95%
L&H Reinsurance	Net income (USD)	241 m	634m	~900m
Corporate Solutions	Combined ratio	91.7%	91.3%	<94%
Swiss Re Group	Net income (USD)	1.0bn	2.5bn	>3bn


## P&C Reinsurance delivers improved underwriting performance




## Corporate Solutions sustains strong underwriting profitability



## L&H Reinsurance profitability returned to pre-pandemic levels



## Increased reinvestment yield in third quarter as rates continued to rise



**Swiss Re** 

<sup>1</sup> From 2021 recurring income yield replaced running yield (income from short term investments, listed equity dividends and real estate investment income added to fixed income and loans already included in running yield metric)


# Financial highlights



## Key figures


			Corporate	Crearin items	Total	Total
USD m, unless otherwise stated	P&C Re	L&H Re	Solutions	Group items	9M 2023	9M 2022
<ul> <li>Premiums earned and fee income</li> </ul>	17 352	11 672	4 007	687	33 718	32 366
Net income/loss	1 504	634	492	-164	2 466	-285
Return on investments	2.5%	4.7%	2.7%	7.9%	3.5%	1.6%
Combined ratio	94.3%		91.3%			
Return on equity					25.9%	-2.1%
Earnings per share	(USD)				8.52	-0.99
	(CHF)				7.65	-0.91
					E. J.	End
					End	End
					9M 2023	FY 2022
<ul> <li>Shareholders' equity</li> </ul>					12 698	12 699
of which unrealised gains					-7 441	-6 935
				_		
Book value per share	(USD)				43.73	43.94
	(CHF)				40.00	40.65

## P&C Reinsurance underwriting result reflects improved pricing and portfolio structure




- Net premiums earned growth of 4.5%, reflecting continued price increases (+5.4% at constant fx rates)
- Underwriting result benefitted from improved margins at year-to-date renewals as well as slightly lower-than-expected large nat cat losses
- Improved investment result primarily reflects higher income from fixed income securities

Combined ratio (%)



• 9M 2023 combined ratio reflects large nat cat losses of 6.5%pts, large man-made losses of 0.9%pts, adverse prior-year development of 1.0%pts, and improved margins






<sup>1</sup> Net operating margin = EBIT / total revenues

m

**Swiss Re** <sup>2</sup> As of 2023, reported combined ratio includes interests on funds withheld (favourable impact of 0.6%pts in 9M 2023) <sup>3</sup> 2021 figures restated for Group items re-segmentation (figures before 2021 are not restated)

## L&H Reinsurance net income returned to pre-pandemic levels




- Net premiums earned and fee income increased by 4.2%, supported by growth in transactions (+6.1% at constant fx rates)
- Underwriting performance benefitted from a strong decline in COVID-19 claims, while being adversely impacted by elevated US mortality in winter months and higher-than-expected large individual claims in Q3 2023
- Strong investment result driven by higher interest rates





• Recurring income yield increased by 0.9%pts to 4.0%, reflecting higher reinvestment yields

#### Net income (USD m)




<sup>1</sup> Net operating margin = EBIT / (total revenues – net investment result unit linked)

<sup>2</sup> From 2021 recurring income yield replaced running yield (income from short term investments, listed equity dividends and real estate investment income added to fixed

income and loans already included in running yield metric)

<sup>3</sup> 9M 2021 figures restated for Group items re-segmentation (figures before 2021 are not restated)

## Corporate Solutions maintains strong performance




- Net premiums earned decreased due to the partial sale of elipsLife mid-2022. On a pro-forma<sup>2</sup> basis, premiums increased by 7.4% at constant fx rates, benefitting from new business growth, partially offset by targeted reductions in professional liability
- Higher underwriting margin confirms the improved resilience of the portfolio and disciplined underwriting approach
- Investment result benefitted primarily from higher recurring income



• 9M 2023 combined ratio reflects large nat cat losses of 2.1%pts, large man-made losses of 3.8%pts, and favourable prior-year development of 1.4%pts





<sup>1</sup> Net operating margin = EBIT / total revenues

m

Swiss Re<sup>2</sup> Including medical business of Elips Versicherungen AG in Ireland and excluding parts of elipsLife sold to Swiss Life International (effective 1 July 2022)

<sup>3</sup> Figures for 9M 2020 restated to include impact of elipsLife, which as of 1 January 2021 is reported as part of Corporate Solutions (figures before 2020 are not restated)


# Strong investment result mainly driven by higher recurring income

Return on investments (ROI)

Investment portfolio positioning (USD bn)




in 9M 2022



- ROI of 3.5% for 9M 2023. comprised of net investment income (+3.1%) and net realised gains (+0.4%)
- Allowance for credit losses<sup>1</sup> increased by USD 8m in 9M 2023

- Decrease in government bonds driven by net sales
- Credit investments increased mainly due to net purchases
- Decrease in equities and alternatives reflects significant reduction of listed equity exposure as well as sales of real estate

Net investment income (USD m) Recurring income yield<sup>3</sup> (%)



- 9M 2023 recurring income yield of 3.5% is well above prioryear periods, reflecting a positive impact from reinvestments into higher yields (fixed income reinvestment yield of 4.9% in Q3 2023)
- Overall net investment income of USD 2.4bn is significantly above the prior-year period, driven by a higher contribution from fixed income and short-term investments

<sup>1</sup> Reflects adoption of ASC 326 Financial Instruments – Credit Losses

<sup>2</sup> Includes credit bonds, mortgages and other loans



Swiss Re <sup>3</sup> From 2021 recurring income yield replaced running yield (income from short term investments, listed equity dividends and real estate investment income added to fixed income and loans already included in running yield metric)

Other

# Appendix



## Business segment results 9M 2023 Income statement

			Corporate			Total	Total
USD m	P&C Re	L&H Re	Solutions	Group items	Consolidation	9M 2023	9M 2022
Revenues							
Gross premiums written	20 3 9 3	12 730	5 716	1 084	-770	39 1 5 3	37 576
Net premiums written	19072	11 636	3 888	883	-	35 479	34 590
Change in unearned premiums	-1 720	-150	119	-196	-	-1 947	-2 422
Premiums earned	17 352	11 486	4 007	687	-	33 532	32 168
Fee income from policyholders	-	186	-	-	-	186	198
Net investment income/loss – non-participating	1 488	1 356	279	189	-358	2 954	2 098
Net realised investment gains/losses – non-participating	5	211	21	260	-	497	-145
Net investment result – unit-linked business	-	-7	-	-	-	-7	-85
Other revenues	19	-	3	417	-388	51	44
Total revenues	18 864	13 232	4 310	1 553	-746	37 213	34 278
Expenses							
Claims and claim adjustment expenses	-11 380	-	-2 452	-77	-	-13 909	-15 334
Life and health benefits	-	-9 729	-	-455	-	-10 184	-10 422
Return credited to policyholders	-	-247	-	-	-	-247	-160
Acquisition costs	-4 054	-1 600	-555	-193	-	-6 402	-5 801
Operating expenses	-1 036	-665	-651	-816	388	-2 780	-2 476
Total expenses	-16 470	-12 241	-3 658	-1 541	388	-33 522	-34 193
Income/loss before interest and tax	2 394	991	652	12	-358	3 691	85
Interest expenses	-470	-182	-20	-168	358	-482	-454
Income/loss before income tax expense/benefit	1 924	809	632	-156	-	3 209	-369
Income tax expense/benefit	-417	-175	-135	-8	-	-735	89
Net income/loss before attribution of non-controlling interests	1 507	634	497	-164	-	2 474	-280
Income/loss attributable to non-controlling interests	-3	-	-5	-	-	-8	-5
Net income/loss attributable to shareholders	1 504	634	492	-164	-	2 466	-285

## Business segment results Q3 2023 Income statement

			Corporate			Total	Total
USD m	P&C Re	L&H Re	Solutions	Group items	Consolidation	Q3 2023	<u>Q3 2022</u>
Revenues							
Gross premiums written	5 0 7 7	4 0 2 8	2 1 4 4	302	-172	11 379	10 973
Net premiums written	4 753	3 6 5 6	1 516	218	-	10143	10 008
Change in unearned premiums	1 230	184	-75	28	-	1 367	1 099
Premiums earned	5 983	3 840	1 441	246	-	11 510	11 107
Fee income from policyholders	-	71	-	-	-	71	55
Net investment income/loss – non-participating	592	483	107	56	-147	1 091	787
Net realised investment gains/losses – non-participating	46	133	2	192	-	373	95
Net investment result – unit-linked business	-	8	-	-	-	8	-13
Other revenues	5	-	1	142	-134	14	9
Total revenues	6 6 2 6	4 535	1 551	636	-281	13 067	12 040
Expenses							
Claims and claim adjustment expenses	-3 976	-	-915	-41	-	-4 932	-6 399
Life and health benefits	-	-3 282	-	-153	-	-3 435	-3 335
Return credited to policyholders	-	-91	-	-	-	-91	-70
Acquisition costs	-1 294	-551	-181	-51	-	-2 077	-1 855
Operating expenses	-377	-230	-226	-316	134	-1 015	-817
Total expenses	-5 647	-4 154	-1 322	-561	134	-11 550	-12 476
Income/loss before interest and tax	979	381	229	75	-147	1 517	-436
Interest expenses	-190	-66	-7	-47	147	-163	-154
Income/loss before income tax expense/benefit	789	315	222	28	-	1 354	-590
Income tax expense/benefit	-186	-74	-51	-19	-	-330	150
Net income/loss before attribution of non-controlling interests	603	241	171	9	-	1 024	-440
Income/loss attributable to non-controlling interests	-3	-	-2	-	-	-5	-2
Net income/loss attributable to shareholders	600	241	169	9	-	1 019	-442

## Business segment results 9M 2023 Balance sheet

			Corporate			End	End
30 September 2023, USD m	P&C Re	L&H Re	Solutions	Group items	Consolidation	9M 2023	FY 2022
Assets							
Fixed income securities	39 0 97	24 808	7 593	577	-	72 075	74 573
Equity securities	51	52	12	34	-	149	2 1 1 4
Other investments	20 034	4 781	495	3 207	-7 387	21 1 30	16 068
Short-term investments	3 872	2 618	1 343	293	-	8 1 2 6	8 907
Investments for unit-linked business	-	291	-	-	-	291	330
Cash and cash equivalents	2 8 2 6	979	957	526	-	5 288	4 0 7 7
Deferred acquisition costs	2 7 7 1	4 4 4 8	441	482	-	8 1 4 2	8 1 2 1
Acquired present value of future profits	-	737	-	-	-	737	794
Reinsurance recoverable	1 566	2 217	6 2 4 5	265	-4 005	6 288	6 507
Other reinsurance assets	20 1 2 4	12 896	2 985	552	-859	35 698	32 074
Goodwill	1 855	1 795	194	29	-	3 873	3 863
Other	16 630	12 355	4 3 7 5	5 2 7 1	-24 212	14 419	13 248
Total assets	108 826	67 977	24 640	11 236	-36 463	176 216	170 676
Liabilities							
Unpaid claims and claim adjustments expenses	57 860	16 934	13 939	790	-4 006	85 517	85 418
Liabilities for life and health policy benefits	-	19136	625	890	-	20 651	20 925
Policyholder account balances	-	4 7 2 7	-	-	-	4 7 2 7	4 850
Other reinsurance liabilities	20 1 3 5	2 1 1 7	5 4 5 8	670	-1 283	27 097	23 505
Short-term debt	298	266	499	499	-296	1 266	786
Long-term debt	5 610	7 359	-	2 640	-5 872	9 7 3 7	10 252
Other	20 357	13 302	1 609	4 0 5 0	-25 006	14 312	12 131
Total liabilities	104 260	63 841	22 130	9 539	-36 463	163 307	157 867
Equity							
Shareholders' equity	4 4 8 4	4 1 3 6	2 381	1 697	-	12 698	12 699
Non-controlling interests	82	-	129	-	-	211	110
Total equity	4 566	4 136	2 510	1 697	-	12 909	12 809
Total liabilities and equity	108 826	67 977	24 640	11 236	-36 463	176 216	170 676

## Total equity and ROE 9M 2023

	Total
USD m	9M 2023
Shareholders' equity at 31 December 2022	12 699
Net income attributable to shareholders	2 466
Dividends	-1 850
Net change in unrealised gains/losses	-506
Other (incl. fx)	-111
Shareholders' equity at 30 September 2023	12 698
Non-controlling interests	211
Total equity at 30 September 2023	12 909


ROE calculation	Total
USD m	9M 2023
Net income attributable to shareholders	2 466
Opening shareholders' equity	12 699
Average shareholders' equity	12 699
ROE 9M 2023 <sup>1</sup>	25.9%

#### Shares outstanding<sup>2</sup>

in millions	
As at 30 September 2023	290.4
Weighted average	289.6

## Change in shareholders' equity mainly driven by net income and dividends

USD m



<sup>1</sup> Includes a USD 33m impact from the adoption of ASC 326 Financial Instruments – Credit Losses

Swiss Re<sup>2</sup> Includes USD -167m due to foreign currency translation adjustments, USD -95m in retained earnings from the adoption of ASC 326 Financial Instruments – Credit Losses and USD +116m from Treasury shares

18

## P&C underwriting performance P&C Reinsurance and Corporate Solutions

	Combined ratio			Main drivers of change year-to-date	Net premiums earned (USD m)		
P&C Reinsurance	Q3 <b>2022</b>	Q3 <b>2023</b> 1	9M <b>2022</b>	9M <b>2023</b> 1		Q3 <b>2023</b>	9M <b>2023</b>
Property	127.0%	64.0%	110.4%	70.5%	• Improvement reflects strong underlying profitability and favourable large nat cat experience	2 813	7 053
Casualty	117.7%	138.8%	106.1%	124.6%	<ul> <li>Result includes reserve additions in liability and motor. Q3 2023 result reflects significant assumption-driven<sup>2</sup> reserve additions in US liability</li> </ul>	2 059	7 127
Specialty	102.5%	85.3%	95.3%	<b>79.3</b> %	Strong result supported by favourable current and prior-year developments	1 111	3 172
Total	119.5%	93.7%	106.1%	94.3%		5 983	17 352


#### **Corporate Solutions**

Property	87.7%	<b>74.7</b> %	74.0%	<b>68.9</b> %	<ul> <li>Improvement reflects profitable new business and favourable large nat cat experience</li> </ul>	558	1 461
Casualty <sup>3</sup>	105.7%	111.0%	104.0%	110.7%	<ul> <li>Performance mainly impacted by prior-year man-made losses and assumption updates<sup>2</sup> in professional liability</li> </ul>	557	1 641
Specialty	78.7%	87.7%	94.6%	<b>92.2</b> %	<ul> <li>Improvement vs. prior-year period mainly driven by enhanced profitability of credit book and lower reserve additions related to the Ukraine war</li> </ul>	326	905
elipsLife <sup>3</sup>			108.7%		elipsLife business partially sold mid-2022	0	0
Total	92.9%	91.7%	93.1%	91.3%		1 441	4 007

1 As of 2023, reported combined ratio includes interests on funds withheld (Reinsurance with favourable impact of 0.6%pts in 9M 2023, Corporate Solutions with 0.0%pts impact) Assumption-driven reserve increases represent additions to incurred but not reported (IBNR) reserves

<sup>3</sup> Medical business of Elips Versicherungen AG in Ireland reported within Casualty for Q3/9M 2022 (restated) and Q3/9M 2023

## P&C Reinsurance: combined ratio split



#### Main drivers of change year-to-date

- Current accident year (CAY) loss ratio excluding large losses benefitted from improved margins at year-to-date renewals
- Acquisition cost ratio in 9M 2023 in-line with prior-year period
- Operating expenses mainly impacted by higher variable compensation assumptions and unfavourable fx movements
- Large nat cat losses of USD 1 075m<sup>2,3</sup> (vs. USD 2 541m in 9M 2022)
- Large man-made losses of USD 149m (vs. USD 216m in 9M 2022, impacted by reserves related to the Ukraine war)
- Prior-year development of USD -182m (vs. USD -422m in 9M 2022), of which USD -151m in Q3 2023, reflecting significant additions to US liability reserves, the majority of which were assumption-driven<sup>4</sup>

- <sup>1</sup> Interests on funds withheld / net premiums earned; as of 2023, reported combined ratio includes interests on funds withheld (USD 102m for 9M 2023)
- **Swiss Re** <sup>2</sup> Net of reinstatement premiums of USD 52m <sup>3</sup> Budget for expected large pat cat losses in 9

<sup>e</sup> <sup>3</sup> Budget for expected large nat cat losses in 9M 2023 is ~75% of full-year budget of USD 1.9bn

<sup>4</sup> Assumption-driven reserve increases represent additions to incurred but not reported (IBNR) reserves

Note: large losses are defined as losses USD >20m in P&C Reinsurance

## Corporate Solutions: combined ratio split

**Quarterly performance** (%)

100 100 92.9 93.1 95 95 91.3 91.7 7.6 4.5 2.1 4.4 90 90 3.8 6.2 2.8 85 85 80 80 16.2 14.3 15.7 14.8 75 75 70 70 65 65 60 60 57.5 55 57.2 55 56.7 55.0 0 0 -0.1 -0.8 0.0 -4.6 -5 -5 03 2022 Q3 2023 9M 2022 9M 2023 CAY losses excl. large losses Operating expenses Prior-year development Large nat cat losses Acquisition costs Interests on funds withheld<sup>1</sup> Large man-made losses

#### Main drivers of change year-to-date

- Current accident year (CAY) loss ratio excluding large losses confirms improved resilience of the business and disciplined underwriting
- Acquisition cost ratio remains broadly stable despite impact from the partial sale of elipsLife mid-2022
- Operating expense ratio increased primarily due to execution of strategic investments, higher variable compensation assumptions and partial sale of elipsLife business which operated at a lower expense ratio
- Large nat cat losses of USD 86m (vs. USD 187m in 9M 2022)
- Large man-made losses of USD 153m (vs. USD 257m in 9M 2022, primarily marked by reserves related to the Ukraine war)
- Favourable prior-year development of USD 56m (vs. USD 110m in 9M 2022)

Swiss Re

Note: large losses are defined as losses USD >10m in Corporate Solutions <sup>1</sup> Interests on funds withheld / net premiums earned; as of 2023 reported combined ratio includes interests on funds withheld (USD 1m in 9M 2023)

Year-to-date performance (%)

# Return on investments (ROI) 9M 2023

USD m	P&C Re	L&H Re	Corporate Solutions	Group items	Consolidation	<b>Total</b> 9M <b>2023</b>	<b>Total</b> 9M <b>2022</b>
Investment related net investment income	1 269	1 027	279	187	-358	2 404	1 655
Fixed income	799	762	173	13	-	1 747	1 355
Equities and alternative investments – incl. RE, PE, HF	323	25	2	1	-	351	365
Other	334	316	122	189	-375	586	210
Investment expenses	-187	-76	-18	-16	17	-280	-275
Investment related net realised gains/losses	-109	230	-21	178	-	278	-418
Fixed income	-220	-4	-22	-1	-	-247	-318
Equities and alternative investments – incl. RE, PE, HF	436	2	13	148	-	599	-671
Other	-325	232	-12	31	-	-74	571
Other revenues	-	-	-	-	-	-	-
Investment related operating income	1 160	1 257	258	365	-358	2 682	1 237
Less income not related to investment return <sup>1</sup>	-133	-95	-65	-82	194	-181	-49
Basis for ROI	1 027	1 162	193	283	-164	2 501	1 188
Average invested assets	55 661	33 047	9 677	4 778	-7 845	95 318	99 409
ROI	2.5%	4.7%	2.7%	7.9%	n.a.	3.5%	1.6%
Insurance related net investment income	219	329	-	2	-	550	443
Insurance related net realised gains/losses	11	31	30	-1	-	71	108
Foreign exchange gains/losses	103	-50	12	83	-	148	165
Net investment income/loss – non participating	1 488	1 356	279	189	-358	2 954	2 098
Net realised investment gains/losses – non participating	5	211	21	260	-	497	-145


• Increase in investment related net investment income driven by higher contribution from fixed income as well as short-term investments in 'other'

• Investment related net realised gains driven by real estate sales and mark-to-market gains on equities and alternative investments, partially offset by losses from derivatives and targeted sales of lower yielding fixed income securities

# Return on investments (ROI) Q3 2023

USD m	P&C Re	L&H Re	Corporate Solutions	Group items	Consolidation	Total Q3 2023	<b>Total</b> Q3 <b>2022</b>
Investment related net investment income	490	372	106	56	-147	877	638
Fixed income	290	254	65	5	-	614	473
Equities and alternative investments – incl. RE, PE, HF	130	8	-	-8	-	130	163
Other	137	135	48	67	-151	236	102
Investment expenses	-67	-25	-7	-8	4	-103	-100
Investment related net realised gains/losses	40	131	-11	173	-	333	-49
Fixed income	-180	-5	-12	-	-	-197	-86
Equities and alternative investments – incl. RE, PE, HF	314	-1	2	143	-	458	-100
Other	-94	137	-1	30	-	72	137
Other revenues	-	-	-	-	-	-	-
Investment related operating income	530	503	95	229	-147	1 210	589
Less income not related to investment return <sup>1</sup>	-60	-49	-26	-39	95	-79	-26
Basis for ROI	470	454	69	190	-52	1 131	563
Average invested assets	54 399	32 681	9 662	3 660	-6 635	93 767	95 453
ROI	3.5%	5.6%	2.9%	20.8%	n.a.	4.8%	2.4%
Insurance related net investment income	102	111	1	-	-	214	149
Insurance related net realised gains/losses	16	15	7	-1	-	37	8
Foreign exchange gains/losses	-10	-13	6	20	-	3	136
Net investment income/loss – non participating	592	483	107	56	-147	1 091	787
Net realised investment gains/losses – non participating	46	133	2	192	-	373	95

## Overall investment portfolio



USD bn <sup>1</sup>	P&C Re	L&H Re	Corporate Solutions		Consolidation	<b>End</b> 9M 2023	End FY <b>2022</b>
Cash and cash equivalents	2.8	1.0	1.0	0.5	-	5.3	4.1
Short-term investments	3.9	2.6	1.3	0.3	-	8.1	8.9
Government bonds	19.3	9.1	3.0	0.2	-	31.6	37.7
Credit bonds	19.8	15.7	4.6	0.4		40.5	36.8
Equities <sup>2</sup>	4.2	0.1	0.1	0.8		5.2	6.5
Mortgages and other loans <sup>3</sup>	4.9	4.1	0.2	2.0	-6.2	5.0	4.3
Other investments (incl. policy loans) <sup>4</sup>	11.0	0.6	0.2	0.5	-1.2	11.1	7.4
Total	65.9	33.2	10.4	4.7	-7.4	106.8	105.7


<sup>1</sup> Includes securities lending, repo assets and collateral balances (compared to investment portfolio positioning on page 12)

<sup>2</sup> Includes equity securities, private equity and Principal Investments

**Swiss Re** <sup>3</sup> At amortised cost

<sup>4</sup> Includes real estate at carrying value

## Fixed income securities




- Decrease in government bonds driven by net sales
- Increase in credit investments reflects net purchases
- Credit bonds include corporate bonds (USD 35.9bn) and securitised products (USD 4.6bn)

## Equities and alternative investments

USD m	<b>End</b> FY <b>2022</b>	<b>End</b> 9M <b>2023</b>
Equity securities	1 535	111
Private equity	3 301	3 656
Hedge funds	9	6
Real estate <sup>1</sup>	5 752	5 368
Principal Investments	1 660	1 449
Equity securities	579	38
Private equity	1 081	1 411
Total market value	12 257	10 590

- Significant reduction in equity exposure in Q2 2023
- Increase in private equity driven by net purchases and valuation gains
- Decrease in real estate driven by sales in Q3 2023
- Decrease in Principal Investments driven by sale of stake in CPIC, partially offset by a change in accounting treatment of FWD following the completion of its restructuring



## Corporate calendar and contacts

## **Corporate calendar**

#### 2023

01 December Investo

## Investors' Day 2023

#### 2024

16 February	Annual Results 2023
13 March	Publication of Annual Report 2023
12 April	160 <sup>th</sup> Annual General Meeting
16 May	Q1 2024 Results

Zurich

Conference call

Zurich Conference call

#### **Investor Relations contacts**

#### Hotline

### E-mail

Investor\_Relations@swissre.com

Thomas Bohun +41 43 285 8118

+41 43 285 4444

Martijn Tielens +41 43 285 2620 Nicole Cooke +41 43 285 8722 Marcel Fuchs +41 43 285 3611

Caroline Walker +41 43 285 5561

### Swiss Re





## Cautionary note on forward-looking statements

Certain statements and illustrations contained herein are forward-looking. These statements (including as to plans, objectives, targets, and trends) and illustrations provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical fact or current fact.

Forward-looking statements typically are identified by words or phrases such as "anticipate", "target", "aim", "assume", "believe", "continue", "estimate", "estimate", "estimate", "anticipate", "intend" and similar expressions, or by future or conditional verbs such as "will", "may", "should", "would" and "could". These forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Swiss Re's (the "Group") actual results of operations, financial condition, solvency ratios, capital or liquidity positions or prospects to be materially different from any future results of operations, financial condition, solvency ratios, capital or liquidity positions or prospects expressed or implied by such statements or cause the Group to not achieve its published targets. Such factors include, among others:

- macro-economic events or developments including increased volatility of, and/or disruption in, global capital, credit, foreign
  exchange and other markets and their impact on the respective prices, interest and exchange rates and other benchmarks
  of such markets, and historically high inflation rates;
- the frequency, severity and development of, and losses associated with, insured claim events, particularly natural
  catastrophes, man-made disasters, pandemics, social inflation litigation, acts of terrorism or acts of war, including the
  ongoing war in Ukraine, and any associated governmental and other measures such as sanctions, expropriations and
  seizures of assets as well as the economic consequences of the foregoing;
- the Group's ability to comply with standards related to environmental, social and governance ("ESG"), sustainability and corporate social responsibility ("CSR") matters and to fully achieve goals, targets, or ambitions related to such matters;
- the Group's ability to achieve its strategic objectives;
- legal actions or regulatory investigations or actions, including in respect of industry requirements or business conduct rules of general applicability, the intensity and frequency of which may also increase as a result of social inflation;
- central bank intervention in the financial markets, trade wars or other protectionist measures relating to international trade arrangements, adverse geopolitical events, domestic political upheavals or other developments that adversely impact global economic conditions;
- mortality, morbidity and longevity experience;
- the cyclicality of the reinsurance sector;
- the Group's ability to maintain sufficient liquidity and access to capital markets, including sufficient liquidity to cover potential recapture of reinsurance agreements, early calls of debt or debt-like arrangements and collateral calls due to actual or perceived deterioration of the Group's financial strength or otherwise;
- the Group's inability to realise amounts on sales of securities on the Group's balance sheet equivalent to their values recorded for accounting purposes;
- the Group's inability to generate sufficient investment income from its investment portfolio, including as a result of fluctuations in the equity and fixed income markets, the composition of the investment portfolio or otherwise;
- changes in legislation and regulation or the interpretations thereof by regulators and courts, affecting the Group or its ceding companies, including as a result of comprehensive reform or shifts away from multilateral approaches to regulation of global operations;

- matters negatively affecting the reputation of the Group, its board of directors or its management;
- the lowering, loss or giving up of one of the financial strength or other ratings of one or more companies in the Group, and developments adversely affecting its ability to achieve improved ratings;
- uncertainties in estimating reserves, including differences between actual claims experience and underwriting and reserving assumptions, in particular in Property & Casualty Reinsurance due to higher costs caused by inflation and supply chain issues;
- policy renewal and lapse rates;
- the outcome of tax audits, the ability to realise tax loss carryforwards and the ability to realise deferred tax assets (including by reason of the mix of earnings in a jurisdiction or deemed change of control), which could negatively impact future earnings, and the overall impact of changes in tax regimes on the Group's business model;
- changes in accounting estimates or assumptions that affect reported amounts of assets, liabilities, revenues or expenses, including contingent assets and liabilities as well as changes in accounting standards, practices or policies;
- strengthening or weakening of foreign currencies;
- reforms of, or other potential changes to, benchmark reference rates;
- failure of the Group's hedging arrangements to be effective;
- significant investments, acquisitions or dispositions, and any delays, unforeseen liabilities or other costs, lower-thanexpected benefits, impairments, ratings action or other issues experienced in connection with any such transactions;
- extraordinary events affecting the Group's clients and other counterparties, such as bankruptcies, liquidations and other credit-related events;
- changing levels of competition;
- the effects of business disruption due to terrorist attacks, cyberattacks, natural catastrophes, public health emergencies, hostilities or other events;
- limitations on the ability of the Group's subsidiaries to pay dividends or make other distributions; and
- operational factors, including the efficacy of risk management and other internal procedures in anticipating and managing the foregoing risks.

These factors are not exhaustive. The Group operates in a continually changing environment and new risks emerge continually. Readers are cautioned not to place undue reliance on forward-looking statements. Swiss Re undertakes no obligation to publicly revise or update any forward-looking statements, whether as a result of new information, future events or otherwise.

This communication is not intended to be a recommendation to buy, sell or hold securities and does not constitute an offer for the sale of, or the solicitation of an offer to buy, securities in any jurisdiction, including the United States. Any such offer will only be made by means of a prospectus or offering memorandum, and in compliance with applicable securities laws.

## Legal notice

©2023 Swiss Re. All rights reserved. You may use this presentation for private or internal purposes but note that any copyright or other proprietary notices must not be removed. You are not permitted to create any modifications or derivative works of this presentation, or to use it for commercial or other public purposes, without the prior written permission of Swiss Re.

The information and opinions contained in the presentation are provided as at the date of the presentation and may change. Although the information used was taken from reliable sources, Swiss Re does not accept any responsibility for its accuracy or comprehensiveness or its updating. All liability for the accuracy and completeness of the information or for any damage or loss resulting from its use is expressly excluded.

## Swiss Re